Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation

Experimental Cell Research

Volumn 315, Issue 8, 2009, Pages 1458-1467

  Natalishvili, Natalia ^a   Axelson, Magnus ^a,b   Girnita, Leonard ^a   Larsson, Olle ^a   Vasilcanu, Daiana ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

H RasV12; IGF 1R; Oncogene; Polyoma middle T antigen; R ; Transformation

Indexed keywords

PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; VIRUS MIDDLE T ANTIGEN;

AGAR MEDIUM; ANIMAL CELL; ARTICLE; BETA CHAIN; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 64449085763     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.01.008     Document Type: Article

References (56)

1. Adams T.E., Epa V.C., Garrett T.P., and Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 57 (2000) 1050-1093
2. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res. 55 (1995) 249-252
3. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19 (2000) 5574-5581
4. Baserga R., Hongo A., Rubini M., Prisco M., and Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta Rev. Cancer 1332 (1997) F105-F126
5. Baserga R., Peruzzi F., and Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 107 (2003) 873-877
6. All-Ericsson C., Girnita L., Seregard S., Bartolazzi A., Jager M.J., and Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Investig. Ophthalmol. Vis. Sci. 43 (2002) 1-8
7. Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., and Larsson O. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60 (2000) 5278-5283
8. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92 (2005) 2097-2101
9. Ullrich A., Gray A., Tam A.W., Yangfeng T., Tsubokawa M., Collins C., Henzel W., Lebon T., Kathuria S., Chen E., Jacobs S., Francke U., Ramachandran J., and Fujitayamaguchi Y. Insulin-like growth factor-i receptor primary structure - comparison with insulin-receptor suggests structural determinants that define functional specificity. EMBO J. 5 (1986) 2503-2512
10. Ward C.W., Garrett T.P.J., McKern N.M., Lou M., Cosgrove L.J., Sparrow L.G., Frenkel M.J., Hoyne P.A., Elleman T.C., Adams T.E., Lovrecz G.O., Lawrence L.J., and Tulloch P.A. The three dimensional structure of the type I insulin-like growth factor receptor. Mol. Pathol. 54 (2001) 125-132
11. Ward C.W., and Garrett T.P.J. Structural relationships between the insulin receptor and epidermal growth factor receptor families and other proteins. Curr. Opin. Drug Discov. Dev. 7 (2004) 630-638
12. Riedemann J., and Macaulay V.M. IGF1R signalling and its inhibition. Endocr. Relat. Cancer 13 (2006) S33-43
13. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev., Cancer 4 (2004) 505
14. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A., Lefkowitz R.J., and Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J. Biol. Chem. 280 (2005) 24412-24419
15. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Vasilcanu D., Girnita A., Lefkowitz R.J., and Larsson O. beta-Arrestin and Mdm2 mediate IGF-1 Receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 282 (2007) 11329-11338
16. Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., and Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11217-11221
17. Liu J.-P., Baker J., Perkins A.S., Robertson E.J., and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type-1 IGF receptor (Igf1r). Cell 75 (1993) 59-72
18. Rosengren L., Vasilcanu D., Vasilcanu R., Fickenscher S., Sehat B., Natalishvili N., Naughton S., Yin S., Girnita A., Girnita L., Axelson M., and Larsson O. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem. Biophys. Res. Commun. 347 (2006) 1059
19. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., and Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64 (2004) 236-242
20. Vasilcanu R., Vasilcanu D., Rosengren L., Natalishvili N., Sehat B., Yin S., Girnita A., Axelson M., Girnita L., and Larsson O. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 27 (2008) 1629-1638
21. Girnita A., All-Ericsson C., Economou M.A., Astrom K., Axelson M., Seregard S., Larsson O., and Girnita L. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 12 (2006) 1383-1391
22. Vasilcanu R., Vasilcanu D., Sehat B., Yin S., Girnita A., Axelson M., and Girnita L. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol. Pharmacol. 73 (2008) 930-939
23. Tornkvist M., Natalishvili N., Xie Y., Girnita A., D'Arcy P., Brodin B., Axelson M., and Girnita L. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem. Biophys. Res. Commun. 368 (2008) 793-800
24. Ulfarsson E., Karstrom A., Yin S., Girnita A., Vasilcanu D., Thoren M., Kratz G., Hillman J., Axelson M., Larsson O., and Girnita L. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin. Cancer Res. 11 (2005) 4674-4680
25. Nussbaum T., Samarin J., Ehemann V., Bissinger M., Ryschich E., Khamidjanov A., Yu X., Gretz N., Schirmacher P., and Breuhahn K. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48 (2008) 146-156
26. Colon E., Zaman F., Axelson M., Larsson O., Carlsson-Skwirut C., Svechnikov K.V., and Soder O. Insulin-like growth factor-I is an important antiapoptotic factor for rat leydig cells during postnatal development. Endocrinology 148 (2007) 128-139
27. Menu E., Jernberg-Wiklund H., De Raeve H., De Leenheer E., Coulton L., Gallagher O., Van Valckenborgh E., Larsson O., Axelson M., Nilsson K., Van Camp B., Croucher P., and Vanderkerken K. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int. J. Cancer 121 (2007) 1857-1861
28. Menu E., Jernberg-Wiklund H., Stromberg T., De Raeve H., Girnita L., Larsson O., Axelson M., Asosingh K., Nilsson K., Van Camp B., and Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107 (2006) 655-660
29. Catrina S.B., Lewitt M., Massambu C., Dricu A., Grunler J., Axelson M., Biberfeld P., and Brismar K. Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br. J. Cancer 92 (2005) 1467-1474
30. Conti L., Regis G., Longo A., Bernabei P., Chiarle R., Giovarelli M., and Novelli F. In the absence of IGF-1 signaling, IFN-{gamma} suppresses human malignant T cell growth. Blood (2006)
31. Fulzele K., DiGirolamo D.J., Liu Z., Xu J., Messina J.L., and Clemens T.L. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282 (2007) 25649-25658
32. Zhu L., and Pollard J.W. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15847-15851
33. Sroka I.C., McDaniel K., Nagle R.B., and Bowden G.T. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate 68 (2008) 463-476
34. Stromberg T., Ekman S., Girnita L., Dimberg L.Y., Larsson O., Axelson M., Lennartsson J., Hellman U., Carlson K., Osterborg A., Vanderkerken K., Nilsson K., and Jernberg-Wiklund H. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107 (2006) 669-678
35. Ning H., Lin G., Fandel T., Banie L., Lue T.F., and Lin C.S. Insulin growth factor signaling mediates neuron-like differentiation of adipose-tissue-derived stem cells. Differentiation 76 (2008) 488-494
36. Spence S.L., Shaffer A.L., Staudt L.M., Amde S., Manney S., Terry C., Weisz K., and Nissley P. Transformation of late passage insulin-like growth factor-i receptor null mouse embryo fibroblasts by SV40 T antigen. Cancer Res. 66 (2006) 4233-4239
37. Girnita L., Girnita A., and Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8247-8252
38. Valentinis B., Morrione A., Taylor S.J., and Baserga R. Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol. Cell. Biol. 17 (1997) 3744-3754
39. Liu J.L., Blakesley V.A., Gutkind J.S., and LeRoith D. The constitutively active mutant Galpha13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor. J. Biol. Chem. 272 (1997) 29438
40. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., and Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14 (1994) 3604
41. Morrione A., DeAngelis T., and Baserga R. Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J. Virol. 69 (1995) 5300-5303
42. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., and McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
43. Bouchard C., Marquardt J., Bras A., Medema R.H., and Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 23 (2004) 2830-2840
44. Yang H., Wen Y.Y., Zhao R., Lin Y.L., Fournier K., Yang H.Y., Qiu Y., Diaz J., Laronga C., and Lee M.H. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res. 66 (2006) 3096-3105
45. Vilgelm A., Lian Z., Wang H., Beauparlant S.L., Klein-Szanto A., Ellenson L.H., and Di Cristofano A. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten± mice. Cancer Res. 66 (2006) 3375-3380
46. Bader A.G., and Vogt P.K. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene 27 (2008) 1179-1182
47. Hakak Y., and Martin G.S. Ubiquitin-dependent degradation of active Src. Curr. Biol. 9 (1999) 1039-1042
48. Lopaczynski W., Terry C., and Nissley P. Autophosphorylation of the insulin-like growth factor i receptor cytoplasmic domain. Biochem. Biophys. Res. Commun. 279 (2000) 955
49. Liao H.J., and Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell 18 (2007) 1064-1072
50. Ni C.Y., Murphy M.P., Golde T.E., and Carpenter G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (New York, N.Y 294 (2001) 2179-2181
51. Koda M., Sulkowski S., Garofalo C., Kanczuga-Koda L., Sulkowska M., and Surmacz E. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm. Metab. Res. Hormon- und Stoffwechselforschung 35 (2003) 794-801
52. Inagaki K., Tiulpakov A., Rubtsov P., Sverdlova P., Peterkova V., Yakar S., Terekhov S., and LeRoith D. A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 92 (2007) 1542-1548
53. Keehn C.A., Saeed S., Bickle K., Khalil F.K., and Morgan M.B. Expression of insulin-like growth factor-I receptor in primary cutaneous carcinomas. J. Cutan. Pathol. 31 (2004) 368-372
54. Nakamura M., Miyamoto S., Maeda H., Zhang S.C., Sangai T., Ishii G., Hasebe T., Endoh Y., Saito N., Asaka M., and Ochiai A. Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers. Clin. Cancer Res. 10 (2004) 8434-8441
55. Mascotti F., Caceres A., Pfenninger K.H., and Quiroga S. Expression and distribution of IGF-1 receptors containing a beta-subunit variant (betagc) in developing neurons. J. Neurosci. 17 (1997) 1447-1459
56. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., Ryan P.D., Come S.E., Burstein H.J., Lesnikoski B.A., Kamma M., Friedman P.N., Gelman R., Iglehart J.D., and Winer E.P. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13 (2007) 1198-1207